FDA ESG NextGen for Regulatory Submissions Blog FDA ESG NextGen for Regulatory Submissions The FDA ESG NextGen for Regulatory Submissions has replaced the FDA’s WebTrader and simplifies pharmaceutical…CertaraJune 25, 2025
Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations Poster Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations Learn how a QSP platform predicts ADA and PK effects in combo immunotherapies like nivolumab…CertaraJune 23, 2025
Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1 Announcement Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1 Radnor, PA – June 20, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in…Danielle PillsburyJune 20, 2025
Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning Publication Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning Due to the highly controlled settings of clinical trials, enrolled subjects may not be fully…Danielle PillsburyJune 19, 2025
QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments Poster QSP Modeling in Cancer Therapy | Advancing Tumor-Selective Treatments Discover how Certara uses QSP modeling to advance the development of KK2269, a bispecific antibody…CertaraJune 18, 2025
From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara On-Demand Webinar From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara Discover the Real-World Impact of Model-Based Meta-Analysis. Hear from experts, see case studies to advance…CertaraJune 18, 2025
How is the pharmaceutical industry addressing global health inequities? Press Coverage How is the pharmaceutical industry addressing global health inequities? Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…CertaraJune 17, 2025
A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3 Poster A minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3 Explore a cutting-edge minimal PBPK/PD oncology mouse model for 212Pb-based Radio-DARPin MP0712, meticulously designed to…CertaraJune 16, 2025
How a budget-impact analysis complements cost-effectiveness to present a balanced economic outlook Blog How a budget-impact analysis complements cost-effectiveness to present a balanced economic outlook June 16, 2025 Editor’s note: This is the third of four articles in our series…Simona ColucciJune 16, 2025
Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power Announcement Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power June 16, 2025 RADNOR, PA – June 16, 2025 – Certara, Inc. (Nasdaq: CERT), a…CertaraJune 16, 2025